ADC Therapeutics SA

ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates ( ADCs ), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC. ZYNLONTA received accelerated approval from the U.S. Food and Drug Administration ( FDA ) and conditional approval from the European Commission, China National Medical Products Administration ( NMPA ) and Health Canada for the treatment of relapsed or refractory DLBCL after two or more lines of systemic therapy. We are pursuing expansion of ZYNLONTA internationally, and into earlier lines of diffuse large B-cell lymphoma ( DLBCL ) through our LOTIS-5 confirmatory Phase 3 clinical trial (rituximab combination) and LOTIS-7 Phase 1b clinical trial (bispecific combination) as well as into indolent lymphomas, including marginal zone lymphoma ( MZL ) and follicular lymphoma ( FL ), through investigator-initiated trials ( IITs ) at leading institutions. Headquartered in Lausanne (Biop le), Switzerland, with operations in New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical development to manufacturing and commercialization. Our Product and Pipeline The following table provides an overview of our current approved product and pipeline: In addition to the current approved product and pipeline above, IND-enabling activities for ADCT-241 (the Company’s exatecan-based, prostate-specific membrane antigen (PSMA)-targeting ADC) were completed at the end of 2025.